Trial NC-HEM-14-1


Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises.

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Other
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Ilene Weitz, M.D.
Other Trial Staff:  Christine Duran, Coordinator, Ibrahim Syed, Coordinator, Melissa Peralta, D.M., Niranjan Bhatt, D.M., Sondra Ortiz, R.N., Teresa Olea, R.N.

Staff may log in to see study documents.







For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.